Navigation Links
US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings

HOUSTON, June 2 /PRNewswire/ -- Physicians affiliated with the US Oncology Research Network are presenting the results of their clinical research at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) held May 30 - June 3, 2008 in Chicago.

Dr. Joyce O'Shaughnessy of Texas Oncology-Baylor Charles A Sammons Cancer Center, an affiliate of US Oncology, gave an oral presentation on findings from a randomized Phase III trial that studied lapatanib (L) alone and in combination with trastuzumab (T) in patients with HER2+ metastatic breast cancer who progressed on trastuzumab. The research is the largest study of two targeted agents in HER2+ metastatic breast cancer and the first to demonstrate the synergy of lapatanib and trastuzumab in a Phase III setting.

The research found that improved clinical outcome was achieved with the combination of L+T in patients progressing on T-based therapy and without substantial change in the side-effect profile. The role of combined anti-HER2 therapy, in combination with chemotherapy, in less heavily pretreated patients with early stage disease is ongoing in the Adjuvant L and/or T Treatment Optimization (ALTTO) study.

"More complete HER2 blockade with lapatinib and trastuzumab benefits patients whose metastatic breast cancer (MBC) is progressing in spite of trastuzumab therapy," said Dr. O'Shaughnessy. "This combination is an important new therapeutic strategy for HER2+ MBC patients, one that does not contain chemotherapy. This combination also has exciting potential as treatment for early stage breast cancer, a hypothesis that is being evaluated now in the global ALTTO trial." Dr. O'Shaughnessy serves as co-chair of the US Oncology Breast Cancer Research Committee and associate director for clinical research for US Oncology.

In addition to Dr. O'Shaughnessy's presentation, physicians affiliated with US Oncology participated in 23 oral and poster presentations and published studies at this year's ASCO conference. Findings were presented on a variety of disease states including breast, lung, genitourinary, gynecologic, and melanoma.


-- Nicholas Robert, M.D., Fairfax-Northern Virginia Hematology-Oncology,

co-chair US Oncology Breast Cancer Research Committee: Results of a

Phase II study of pemetrexed as first-line chemotherapy for advanced

or metastatic breast cancer

-- Michael Danso, M.D., Virginia Oncology Associates: Phase II trial of

weekly administration of nabpaclitaxel in combination with bevacizumab

in women with metastatic breast cancer (MBC)

-- Mary Ann Allison, M.D., Comprehensive Cancer Centers of Nevada-Siena

and Joanne Blum, M.D., Ph.D., Texas Oncology-Baylor Charles A Sammons

Cancer Center: Phase II study of eribulin mesylate in patients with

locally advanced or metastatic breast cancer (MBC) previously treated

with an anthracycline, taxane, and capecitabine

-- Sasha Vukelja, M.D., Texas Oncology-Tyler: Phase II and Phase III

study of the efficacy of nab-paclitaxel in patients with poor

prognostic factors or with anthracycline-resistant metastatic breast

cancer (MBC)

-- Frankie Holmes, M.D., Texas Oncology-Houston Memorial City,

US Oncology network associate chair Breast Cancer Research Committee,:

Phase II study on transcriptional profiles of triple receptor-negative

breast cancer: Are Caucasian, Hispanic and African-American different?


-- Charles Weissman, M.D., New York Oncology-Hematology--Latham: Phase

III open-label comparison of gemcitabine/oxaliplatin versus

paclitaxel/carboplatin as first-line therapy for advanced non-small

cell lung cancer (NSCLC)


-- Guru Sonpavde, M.D., Texas Oncology-Deke Slayton Cancer Center: Phase

II study of Azacitidine for castration-resistant prostate cancer

progressing on combined androgen blockade

-- Phillip Periman, M.D., Texas Oncology-Amarillo: Phase II study of

Sunitinib malate for metastatic castration-resistant prostate cancer

following docetaxel-based chemotherapy

-- Allen Cohn, M.D., Rocky Mountain Cancer Centers-Midtown, co-chair,

US Oncology GI Cancer Research Committee: Phase III Panitumumab (pmab)

regimen evaluation in colorectal cancer to estimate primary response

to treatment (PRECEPT): effect of KRAS mutation status on second-line

treatment (tx) with pmab and FOLFIRI

-- Thomas Hutson, D.O., PharmD, Texas Oncology-Baylor Charles A Sammons

Cancer Center, associate chair, US Oncology GU Cancer Research

Committee,: RAD001 plus best supportive care (BSC) vs BSC plus

placebo in patients with metastatic renal cell carcinoma (RCC), which

has progressed on VEGF-TKI therapy: results from a randomized,

double-blind, multicenter Phase III study; Phase III randomized study

of overall survival with sunitinib versus interferon (IFN)-alfa as

first-line treatment of metastatic renal cell carcinoma (mRCC);

Multicenter, Phase I/II study of sunitinib in combination with

docetaxel and prednisone in patients with metastatic

castrate-resistant prostate cancer (mCRPC)-preliminary results;

Biomarker analysis and final results of a phase II renal cell

carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis

inhibitor; A multicenter, prospective Phase II trial of sorafenib in

patients (Pts) with metastatic clear cell renal cell carcinoma

(mccRCC) refractory to prior sunitinib or bevacizumab

-- Kelly Pendergrass, M.D., Kansas City Cancer Center-South:

Characterization of hyperglycemia, hypercholesterolemia, and

hyperlipidemia in patients with advanced renal cell carcinoma

treated with temsirolimus or interferon


-- Michael Teneriello, M.D., Texas Oncology-Austin Central, co-chair,

US Oncology Gynecologic Cancer Research Committee: Phase III trial of

induction gemcitabine (G) or paclitaxel (T) plus carboplatin (C)

followed by elective T consolidation in advanced ovarian cancer (OC):

Interim analysis of induction chemotherapy


-- William Stephenson, M.D., Kansas City Cancer Center-South: PhaseI/II

study of imexon (AMP) plus dacarbazine (DTIC) in patients (Pts) with

metastatic malignant melanoma


-- Roger Lyons, M.D., Cancer Care Centers of South Texas-Medical Center:

Phase II study of single agent clofarabine in previously untreated

older adult patients with acute myelogenous leukemia (AML) unlikely to

benefit from standard induction chemotherapy

Solid Tumors

-- William Stephenson, M.D., Kansas City Cancer Center-South: Phase I

study multicenter study to assess the safety, tolerability, and

pharmacokinetics of AZD4877 administered twice weekly in adult

patients with advanced solid malignancies

-- Robert Raju, M.D., Dayton Oncology & Hematology-Kettering: An open

label Phase I dose escalation study of ADH-1 in combination with

chemotherapy in subjects with N-Cadherin expressing solid tumors

Lymphoma and Plasma Cell Disorders

-- Alan Feiner, M.D., Rocky Mountain Cancer Centers-Rose, and John

Mattern, D.O., Virginia Oncology Associates-Newport News: Primary

therapy of Waldenstrom's macroglobulinemia with bortezomib,

dexamethasone and rituximab: results of WMCTG Clinical Trial 05-180

About US Oncology Research

The US Oncology Research network is an established community-based research operation specializing in all phases of cancer clinical trials. The research network currently has 595 physicians actively enrolling patients, 109 research sites, and is currently involved in 63 open research trials. The network has contributed to the development of 24 of 30 of the latest cancer-fighting drugs approved by the Food and Drug Administration for use. Since 1993, more than 32,000 patients have participated in clinical trials managed by US Oncology network practices. For more information, visit the "Research" section under "Our Services" on the company's Web site,

About US Oncology, Inc.

US Oncology, headquartered in Houston, works closely with physicians, manufacturers and payers to identify and deliver innovative services that enhance patient access to advanced cancer care. US Oncology supports one of the nation's foremost cancer treatment and research networks accelerating the availability and use of evidence-based medicine and shared best practices.

US Oncology's expertise in supporting every aspect of the cancer care delivery system -- from drug development to treatment and outcomes measurement, enables the company to help increase the efficiency and safety of cancer care. According to the company's last quarterly earnings report, US Oncology is affiliated with 1,247 physicians operating in 472 locations, including 91 radiation oncology facilities in 39 states. For more information, visit the company's Web site,

SOURCE US Oncology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
2. New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
3. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
4. BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
5. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
6. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
7. Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
8. Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
9. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
10. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
11. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
Post Your Comments:
(Date:10/12/2015)... New York , October 12, 2015 ... (FMI) delivers key insights on the global vital signs monitoring ... Devices Market: Global Industry Analysis and Opportunity Assessment 2015-2025." The ... at a healthy CAGR of 9.5% and 9.2% in terms ... to factors, regarding which FMI offers major insights in detail ...
(Date:10/12/2015)... Oct. 12, 2015 Beginning October 1, 2015 ... Partner, the fastest growing practice management system for therapists, ... easily converts all patient diagnostic codes from the former ... --> --> Therapy Partner has ... mental health practitioners to easily understand the conversion to ...
(Date:10/12/2015)... , Oct. 12, 2015 Indivior PLC (LON: INDV) ... of Delaware granted the Company,s motion ... Abbreviated New Drug Application (ANDA) No. 205299 to market a ... and naloxone) Sublingual Film (CIII) in the United ... Since August 2013, Indivior has received Paragraph IV certifications ...
Breaking Medicine Technology:
(Date:10/12/2015)... ... October 12, 2015 , ... To help ... its charitable donation to the National Breast Cancer Foundation. The National Breast Cancer ... breast cancer through early detection, education, and support services. , The annual campaign ...
(Date:10/12/2015)... ... October 12, 2015 , ... SQM Group ... a contact channel benchmarking study. Be a part of this insightful ... for improving customer experience, customer journey, contact channel execution and intelligence, workforce optimization, ...
(Date:10/12/2015)... ... ... Holcomb – Kreithen Plastic Surgery and MedSpa, PLLC (“Holcomb – Kreithen”), one of ... Surgery University,” an educational series of mini seminars covering aesthetic and plastic surgery options, ... Saturday, October 24, 2015. , The goal of the event is to provide hands-on ...
(Date:10/12/2015)... ... October 12, 2015 , ... The Asthma and ... Engagement Award by the Patient-Centered Outcomes Research Institute (PCORI) for a new project ... , The project, entitled “Training Patients with Asthma to Understand and Participate in ...
(Date:10/12/2015)... ... October 12, 2015 , ... International law firm Greenberg ... with the U.S. Biomedical Advanced Research and Development Authority (BARDA) reported to be ... ReCell® Autologous Cell Harvesting Device under a U.S. mass casualty preparedness program. ...
Breaking Medicine News(10 mins):